LAB TESTS & BIOMARKERS

Which longevity blood tests actually change what you do this month?

Separating actionable cardiometabolic, renal, and hematologic markers from expensive noise in 80-biomarker panels.

LetsGo Editorial · LetsGo Editorial · 3 November 2026 · 12 min read

Commercial laboratories routinely sell 80- to 100-biomarker panels under the banner of preventive medicine, yet human physiology has far fewer evidence-based levers than there are measurable molecules in peripheral blood.

Clinical laboratory reference intervals are almost universally defined as the central 95% of values observed in a reference population. By definition, 5% of healthy individuals fall outside the normal range on any single test. When an asymptomatic adult orders a panel bundling 80 independent biomarkers, the probability of receiving at least one abnormal flag is 1 minus 0.95 to the 80th power, or 97.6%. In preventive medicine, a blood test has clinical utility only if crossing a specific threshold alters an immediate decision—whether that means changing dietary fat composition, adjusting aerobic or resistance training volume, correcting a micronutrient deficiency, or scheduling a physician visit to discuss prescription therapy. Utility comes from selecting markers that sit directly on causal pathways of human pathology and respond to validated interventions, rather than paying for sprawling arrays that generate diagnostic cascades.

What it is

Venipuncture longevity panels measure circulating proteins, lipids, metabolites, hormones, electrolytes, and cellular indices across 20 to 100 individual assays. From a physiological standpoint, these biomarkers divide into three distinct categories: 1. Causal risk factors: Molecules that directly participate in human tissue pathology. Apolipoprotein B (ApoB) and Lipoprotein(a) [Lp(a)] cross the vascular endothelium, bind to intimal proteoglycans via ionic interactions, and initiate atherosclerotic plaque formation. Elevated blood glucose and fasting insulin drive non-enzymatic glycation of proteins (forming advanced glycation end-products that cross-link collagen) and stimulate vascular smooth muscle cell proliferation via mitogen-activated protein kinase (MAPK) pathways. 2. Functional clearance and organ integrity markers: Molecules that reflect glomerular filtration capacity or cellular turnover. Creatinine and cystatin C reflect renal filtration rate. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are intracellular pyridoxal-phosphate-dependent enzymes released into systemic circulation during hepatocyte or myocyte membrane stress. 3. Integrative systemic markers (Biological Age components): Routine hematologic and biochemical indices that, when combined into validated mathematical models like Levine’s PhenoAge, capture systemic physiological dysregulation. For example, red cell distribution width (RDW)—a measure of volume variability in circulating erythrocytes—and serum albumin are not direct targets for pharmacological manipulation, but in human cohorts they reflect bone marrow erythropoietic fidelity, systemic inflammation, and hepatic synthetic function.

Why it is used

Diagnostic thresholds in standard primary care are set to confirm overt organ failure or advanced disease—such as type 2 diabetes once fasting plasma glucose reaches 126 mg/dL, or stage 3 chronic kidney

disease once estimated glomerular filtration rate (eGFR) falls below 60 mL/min/1.73m². Preventive biomarker testing is used to identify subclinical trajectory shifts 10 to 15 years before those diagnostic thresholds are crossed. In human longitudinal cohorts such as the Whitehall II study (n > 6,000 civil servants followed for over a decade), compensatory hyperinsulinemia—elevated fasting insulin secreted by pancreatic beta cells to overcome skeletal muscle and hepatic insulin resistance—begins 10 to 13 years before fasting blood glucose or HbA1c rises into the diabetic range. Relying solely on fasting glucose misses the early phase of impaired insulin signaling when skeletal muscle GLUT4 translocation responds rapidly to exercise. Similarly, standard lipid panels estimate Low-Density Lipoprotein Cholesterol (LDL-C)—the mass of cholesterol carried inside LDL particles. In individuals with insulin resistance, visceral adiposity, or elevated triglycerides, cholesteryl ester transfer protein (CETP) exchanges triglycerides from VLDL for cholesteryl esters in LDL, producing cholesterol-depleted LDL particles. Their LDL-C appears normal, while the actual number of atherogenic particles (measured by ApoB) is high. In prospective human cohorts (including a UK Biobank analysis of >380,000 adults and the Framingham Offspring Study, n > 3,000), when ApoB and LDL-C are discordant, myocardial infarction risk tracks with ApoB, not LDL-C. Finally, starting point panels are used to calculate composite biological age scores derived from clinical chemistry. Rather than evaluating 40 markers in isolation, models like PhenoAge weight nine routine biomarkers by their Gompertz mortality hazard ratios in human epidemiological datasets (NHANES III and IV, n > 11,000), translating subtle multi-system shifts into a single metric of physiological resilience.

How it helps

In a meta-analysis of 26 human randomized controlled trials by the Cholesterol Treatment Trialists' Collaboration (n ~ 170,000), each 38.7 mg/dL (1 mmol/L) reduction in LDL-C—and its proportional reduction in ApoB-containing particles—reduces major vascular events by 22% per year after the first year of treatment. A biomarker helps only if an out-of-range value triggers a concrete, evidence-backed intervention. Markers That Directly Change Decisions Apolipoprotein B (ApoB): Every atherogenic lipoprotein particle (VLDL, IDL, LDL) contains exactly one molecule of ApoB-100. Measuring ApoB quantifies total atherogenic particle burden in plasma. An elevated ApoB (>80 mg/dL in primary prevention) alters nutrition immediately: replacing dietary saturated fats (butter, fatty meats, coconut oil, which downregulate hepatic LDL receptors) with monounsaturated and polyunsaturated fats, and adding soluble viscous fiber (oats, psyllium, legumes, which bind bile acids in the ileum and upregulate hepatic cholesterol conversion) lowers ApoB, or prompts a physician evaluation for lipid-lowering pharmacotherapy. Lipoprotein(a) [Lp(a)]: Lp(a) is an LDL-like particle with a hydrophilic apolipoprotein(a) glycoprotein covalently bound to ApoB-100 via a disulfide bridge. In humans, it promotes atherogenesis, vascular inflammation (via oxidized phospholipids), and thrombosis (by mimicking plasminogen and competitively inhibiting tissue plasminogen activator). Plasma levels are 80% to 90% genetically determined by kringle IV type 2 repeat polymorphisms at the LPA gene locus and remain stable across adult life. Diet and exercise do not meaningfully lower Lp(a). Measuring it once is essential: if Lp(a) exceeds 50 mg/dL (or 125 nmol/L), the clinical decision is to lower overall cardiovascular risk by driving ApoB (<60 mg/dL), systolic blood pressure (<120 mmHg), and HbA1c to stricter targets under medical supervision. Fasting Insulin and HbA1c: HbA1c measures the percentage of hemoglobin A glycated at the N-terminal valine of the beta chain over the preceding 90 to 120 days (the lifespan of a human erythrocyte). However, variations in red blood cell turnover—caused by iron deficiency, B12/folate status, or foot-strike hemolysis in endurance runners—artificially skew HbA1c by 0.3% to 0.5% in either direction without any change in true mean glucose. Pairing HbA1c with fasting insulin and fasting triglycerides (to calculate HOMA-IR) isolates hepatic and peripheral insulin sensitivity. Elevated fasting insulin (>8 µIU/mL) directly alters training: adding progressive resistance training (which stimulates AMPK-mediated GLUT4 translocation to the sarcolemma independent of insulin) and Zone 2 aerobic training (which increases mitochondrial density and carnitine palmitoyltransferase-1 activity for fatty acid oxidation). Cystatin C with Creatinine: Standard eGFR relies on serum creatinine, a

non-enzymatic breakdown product of skeletal muscle phosphocreatine. In adults who lift weights, carry above-average lean mass, or consume cooked meat or creatine supplements, serum creatinine rises, frequently causing a false-positive flag for stage 3 chronic kidney disease (eGFR < 60 mL/min/1.73m²). Cystatin C is a 13-kDa cysteine protease inhibitor synthesized by all nucleated cells at a constant rate and freely filtered by the glomerulus, unaffected by muscle mass or meat intake. In the CKD-EPI human validation cohorts (n = 5,352 across 13 studies), the combined creatinine-cystatin C equation (eGFRcr-cys) minimized bias and provided the highest precision against measured exogenous filtration markers. Checking cystatin C prevents unnecessary nephrology workups and misplaced restrictions on dietary protein. High-Sensitivity C-Reactive Protein (hs-CRP): Synthesized by hepatocytes in response to interleukin-6 (IL-6) and interleukin-1 beta

secreted by activated macrophages and visceral adipocytes, hs-CRP quantifies systemic innate immune activation. In human randomized controlled trials (JUPITER, n = 17,802; CANTOS, n = 10,061), persistent hs-CRP above 2.0 mg/L independently predicts major cardiovascular events even when LDL-C is below 70 mg/dL, and directly inhibiting

reduces recurrent events by 15%. Because acute viral infections, heavy eccentric exercise, or sleep deprivation in the preceding 48 hours transiently spike hs-CRP, a single reading >2.0 mg/L requires a repeat draw two weeks later. Persistently elevated hs-CRP prompts targeted screening for visceral adiposity, periodontal disease, or obstructive sleep apnea. Ferritin, Transferrin Saturation, and Homocysteine: Ferritin reflects intracellular iron storage in reticuloendothelial macrophages and hepatocytes, while transferrin saturation measures circulating iron bound to transferrin. Both iron depletion (ferritin < 30 ng/mL, which impairs mitochondrial cytochrome c oxidase and thyroid peroxidase activity) and iron overload (transferrin saturation > 45% with elevated ferritin, indicative of HFE hereditary hemochromatosis) are directly actionable via dietary adjustments or therapeutic phlebotomy. Homocysteine is a sulfur-containing intermediate amino acid in the methionine cycle; plasma elevations (>10–12 µmol/L) indicate functional insufficiency of methylcobalamin (B12), 5-methyltetrahydrofolate (B9), or pyridoxal-5'-phosphate (B6), which serve as essential cofactors for methionine synthase and cystathionine beta-synthase in humans. Why Markers Move When Outcomes Do Not Treating every out-of-range value on an 80-marker panel as a therapeutic target fails when the biomarker is not on a causal pathway: 1. The HDL-C Fallacy: Epidemiological cohorts showed an inverse correlation between High-Density Lipoprotein Cholesterol (HDL-C) and coronary disease. However, human Mendelian randomization studies and large randomized controlled trials of CETP inhibitors (torcetrapib, dalcetrapib, and evacetrapib, enrolling >60,000 patients combined) raised HDL-C by 30% to 130% without reducing myocardial infarction or mortality. The mass of cholesterol inside HDL particles (HDL-C) does not reflect the functional capacity of HDL to efflux cholesterol from macrophage foam cells via ABCA1 transporters. Attempting to raise HDL-C pharmacologically changes no clinical outcome. 2. Lipoprotein Subfractionation Noise: Commercial panels charge extra for nuclear magnetic resonance (NMR) spectroscopy or ion mobility assays to measure small, dense LDL versus large, buoyant LDL. While small LDL particles exhibit lower affinity for hepatic LDL receptors and longer plasma residence time in humans, multivariate analyses from cohorts like MESA (Multi-Ethnic Study of Atherosclerosis, n > 6,800) show that once total particle number (ApoB) is accounted for, particle size adds near-zero independent predictive power for cardiovascular events. All ApoB-containing particles <70 nm in diameter cross the endothelium; lowering total ApoB resolves the risk without paying for subfractionation. 3. Single-Timepoint Pulsatile Hormones and Blood Metals: Cortisol, growth hormone, luteinizing hormone, and total testosterone are secreted in circadian and ultradian pulses from the hypothalamic-pituitary-adrenal and gonadal axes. A single venipuncture at 9:30 AM versus 7:30 AM can produce a 30% to 50% difference in serum testosterone or cortisol in the same healthy human due to secretory pulsatility and prior-night REM sleep architecture. Similarly, a spot whole-blood test for heavy metals (mercury, arsenic) reflects acute dietary ingestion over the prior 48 to 72 hours (such as eating a single portion of pelagic fish), not chronic tissue

sequestration.

Who should try it

Adults aged 40 to 65 who have established starting point exercise and dietary habits and want quantitative data to guide medical prevention, structured coaching, or pharmacology gain the highest utility from targeted panels. A physiologically rational testing schedule divides biomarkers into three tiers based on human turnover kinetics: 1. Once-in-a-lifetime constitutional markers: Lipoprotein(a) [Lp(a)] and APOE genotype (for lipid response and neurological risk stratification). Because LPA gene expression is stable across adulthood, retesting Lp(a) every six months outside of a clinical trial for pelacarsen or olpasiran wastes capital. 2. Annual to biannual dynamic core markers (every 6 to 12 months): Complete Blood Count (CBC) with differential (tracking RDW and mean corpuscular volume), Comprehensive Metabolic Panel (CMP: fasting glucose, albumin, ALT, AST, alkaline phosphatase, electrolytes), Cystatin C, ApoB, standard lipid panel (for fasting triglycerides), HbA1c, fasting insulin, hs-CRP, ferritin with transferrin saturation, thyroid-stimulating hormone (TSH) with free T4, 25-hydroxyvitamin D [25(OH)D], homocysteine, and uric acid. 3. Intervention-specific retesting (at 8 to 12 weeks): When a targeted nutritional, training, or pharmacological change is initiated—such as cutting dietary saturated fat, starting a statin or ezetimibe, or correcting iron or vitamin D deficiency—retesting only the perturbed markers at 8 to 12 weeks confirms physiological response. Plasma lipids and ApoB reach a new steady state within 4 to 6 weeks of hepatic LDL receptor upregulation, whereas erythrocyte lifespan requires 90 to 120 days for HbA1c to fully equilibrate.

Measurements that show improvement

Controlled human feeding trials, exercise RCTs, and pharmacological meta-analyses establish specific effect sizes and directional shifts when interventions succeed: ApoB (Target direction: Downward): Replacing 5% to 10% of daily caloric intake from saturated fat with polyunsaturated and monounsaturated fats and increasing soluble fiber lowers ApoB by 8% to 15% (roughly 8 to 15 mg/dL) over 6 to 8 weeks in controlled human metabolic ward and feeding trials. In higher-risk individuals managed by a physician, statin and ezetimibe therapy reduces ApoB by 30% to 60%. Preventive clinical targets are <80 mg/dL for primary prevention, and <60 mg/dL when subclinical coronary plaque or elevated Lp(a) (>50 mg/dL) is present. Fasting Insulin and Triglycerides (Target direction: Downward): In human lifestyle RCTs, losing 5% to 10% of body mass or completing 150 to 300 minutes per week of combined aerobic and resistance training over 12 weeks reduces fasting insulin by 20% to 40% (moving toward <6 to 8 µIU/mL) and lowers fasting triglycerides by 15% to 30% (moving toward <100 mg/dL) via enhanced skeletal muscle glucose uptake and hepatic VLDL-triglyceride clearance. HbA1c (Target direction: Downward): Optimal non-diabetic trajectory is <5.4% (assuming normal erythrocyte lifespan and normal MCV/RDW). In the Diabetes Prevention Program RCT (n = 3,234 overweight adults with impaired glucose tolerance followed for 2.8 years), structured diet and 150 minutes/week of physical activity reduced HbA1c by roughly 0.2% to 0.3% relative to placebo and reduced progression to type 2 diabetes by 58%. hs-CRP (Target direction: Downward): Target <1.0 mg/L. Weight loss of 5% to 10% of total body mass in overweight adults reduces hs-CRP by 0.5 to 1.5 mg/L in human intervention trials by shrinking visceral adipocytes and reducing macrophage IL-6 secretion. 25(OH)D (Target direction: Upward to sufficiency): Correction from deficiency (<20 ng/mL) or insufficiency (20 to 29 ng/mL) into the 30 to 50 ng/mL range. Human meta-analyses of vitamin D RCTs (including VITAL, n = 25,871) demonstrate no reduction in fractures, falls, cardiovascular events, or cancer mortality when raising 25(OH)D above 30 to 50 ng/mL in already-replete adults, while levels >80 to 100 ng/mL increase intestinal calcium absorption and hypercalciuria risk. Homocysteine (Target direction: Downward): Reduction to <10 µmol/L within 8 weeks of correcting vitamin B12, folate, or vitamin B6 insufficiency. Biological Age / PhenoAge (Target direction: Downward relative to chronological age): In Levine's NHANES validation cohorts (n > 11,000), lowering fasting glucose, hs-CRP,

RDW, and alkaline phosphatase while maintaining serum albumin reduces calculated PhenoAge; each 1-year reduction in PhenoAge relative to chronological age corresponds to a 9% lower hazard of all-cause mortality. Trade-offs, Pre-Analytical Artifacts, and Opportunity Cost 1. Diagnostic Cascades from False Positives: Because an 80-marker panel carries a 97.6% mathematical probability of at least one out-of-range result in a healthy human, uncurated panels trigger downstream repeat venipunctures, abdominal ultrasounds, or CT angiograms—adding out-of-pocket costs, radiation exposure, and incidentalomas (benign anatomical findings that lead to invasive tissue biopsies). 2. Pre-Analytical Artifacts: Strenuous or eccentric resistance training within 48 hours of venipuncture disrupts skeletal muscle sarcolemma integrity, releasing intracellular AST, ALT, creatine kinase (CK), and lactate dehydrogenase (LDH) into plasma, which mimics acute hepatocellular injury on a standard metabolic panel. Mild overnight dehydration elevates serum albumin, hematocrit, creatinine, and blood urea nitrogen (BUN) via hemoconcentration. Failing to fast for 10 to 12 hours inflates triglycerides and insulin via chylomicronemia and postprandial beta-cell secretion. Oral biotin (vitamin B7) supplementation taken within 48 to 72 hours of a blood draw saturates streptavidin-biotin capture systems in commercial competitive and sandwich immunoassays, producing falsely low TSH and falsely elevated free T4 andfree T3 readings (mimicking Graves' disease). 3. Financial Opportunity Cost: Commercial 80- to 100-marker bundles cost $400 to $1,200 out of pocket. A focused, causal core panel (CBC, CMP, ApoB, one-time Lp(a), HbA1c, fasting insulin, cystatin C, hs-CRP, ferritin/iron panel, TSH/free T4, 25(OH)D, homocysteine) ordered through a physician or targeted platform costs $150 to $300, preserving capital for interventions with direct physiological return, such as DEXA body composition scanning, cardiopulmonary exercise testing (VO2max), or structured exercise coaching.

Products and services

These LetsGo products and services sit next to this subject. They are not a prescription. A link is not evidence that the product causes the change discussed above. - [Grokki longevity programme](/programs/grokki/longevity) — A coached plan that can track the markers named in this article. - [LetsGo Academy](/academy) — The teaching track for coaches who use these explainers with members.

Practical takeaways

- Order a targeted core panel every 6 to 12 months containing ApoB, fasting insulin, HbA1c, cystatin C (with CMP and CBC), hs-CRP, ferritin/transferrin saturation, TSH/free T4, 25(OH)D, and homocysteine; skip NMR lipoprotein subfractions and spot heavy metal blood tests.
- Measure Lipoprotein(a) [Lp(a)] once in adulthood; if >50 mg/dL (125 nmol/L), do not repeat the test—work with a physician to lower ApoB below 60 mg/dL and systolic blood pressure below 120 mmHg.
- Pair serum creatinine with cystatin C to calculate combined eGFRcr-cys whenever lean muscle mass is above average or creatine monohydrate is used, eliminating false-positive stage 3 kidney disease flags (eGFR <60 mL/min/1.73m²).
- Standardize pre-analytical conditions before every draw: fast 10 to 12 hours, drink 16 to 24 oz of water on waking, stop strenuous exercise for 48 to 72 hours, and stop biotin supplements for 72 hours.
- Apply a strict stop rule to isolated borderline flags on large panels: if an asymptomatic marker (such as hs-CRP >2.0 mg/L or ALT >40 U/L) flags once, standardize pre-analytical conditions and repeat that single assay in 2 to 6 weeks before ordering imaging or starting supplements.

Safety note

Never start, stop, or alter prescription medications based on commercial blood panel results without consulting a licensed physician. Rapidly correcting laboratory abnormalities with high-dose over-the-counter supplements (particularly iron, vitamin D, or methylated B vitamins) without medical supervision can cause iron overload,

hypercalcemia, arrhythmias, or organ damage. Acute symptoms such as chest pain, shortness of breath, or severe unexplained fatigue require immediate medical evaluation rather than outpatient biomarker testing.

Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice, clinical diagnosis, or treatment prescription. Laboratory reference intervals and preventive targets vary by assay methodology, age, sex, and individual medical history. Always review biomarker results with a qualified healthcare professional.

The clinical utility of a blood panel is defined by the interventions it alters, not the number of assays on the report. By isolating causal and actionable human biomarkers—ApoB, one-time Lp(a), fasting insulin, HbA1c, cystatin C, and hs-CRP—while strictly standardizing hydration, fasting, and 48-hour exercise abstinence before venipuncture, adults can avoid the 97.6% false-positive noise of 80-marker panels and direct resources toward nutrition, training, and medical therapies with established human effect sizes.